DÄ internationalArchive19/2007Tyrosine Kinases Are the Targets of New Treatments in Oncology

Review article

Tyrosine Kinases Are the Targets of New Treatments in Oncology

Dtsch Arztebl 2007; 104(19): A-1312

Müller-Tidow, C; Krug, U; Brunnberg, U; Berdel, W E; Serve, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548–57. MEDLINE
2. Emens LA, Davidson NE: Trastuzumab in breast cancer. Oncology (Williston Park) 2004; 18: 1117–28; discussion 31–2, 37–8. MEDLINE
3. Baselga J, Perez EA, Pienkowski T, Bell R: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11(Suppl 1): 4–12. MEDLINE
4. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19): 183–232. MEDLINE
5. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45. MEDLINE
6. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207–25. MEDLINE
7. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42. MEDLINE
8. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34. MEDLINE
9. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005; ASCO Annual Meeting Proceedings Part I. 23(16S): abstract 4.
10. Miller KD: E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421–2. MEDLINE
11. Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45. MEDLINE
12. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348): 994–1004. MEDLINE
13. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389–95. MEDLINE
14. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–41. MEDLINE
15. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813–25. MEDLINE
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32. MEDLINE
17. Chan SK, Gullick WJ, Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer – search and destroy. Eur J Cancer 2006; 42: 17–23. MEDLINE
18. Sandler AB: Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006; 20(5 Suppl 2): 35–40. MEDLINE
19. Motzer RJ, Hutson TE, Tomczak P, et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24(18S): abstract LBA3.
20. New targeted therapy for rare stomach, kidney cancers. FDA Consum 2006; 40: 5.
21. Escudier B, Szczylik C, Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; ASCO Annual Meeting Proceedings Part I. 23(16S): abstract 4510.
22. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544–55. MEDLINE
23. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889–96. MEDLINE
24. Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172–87. MEDLINE
25. Arteaga CL, Baselga J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004; 5: 525–31. MEDLINE
e1. Borg A, Tandon AK, Sigurdsson H, et al.: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332–7. MEDLINE
e2. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283–90. MEDLINE
e3. Hirsch FR, Langer CJ: The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004; 31(1 Suppl 1): 75–82. MEDLINE
e4. Ziada A, Barqawi A, Glode LM, et al.: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60: 332–7. MEDLINE
e5. Kerkela R, Grazette L, Yacobi R, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12: 908–16. MEDLINE
e6. Sun L, Liang C, Shirazian S, et al.: Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116–9. MEDLINE
e7. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109. MEDLINE